- Home
- SLNH vs GOVX Comparison
SLNH vs GOVX Comparison
Compare SLNH & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLNH
- GOVX
- Stock Information
- Founded
- SLNH 1961
- GOVX 2001
- Country
- SLNH United States
- GOVX United States
- Employees
- SLNH N/A
- GOVX N/A
- Industry
- SLNH EDP Services
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- SLNH Technology
- GOVX Health Care
- Exchange
- SLNH Nasdaq
- GOVX Nasdaq
- Market Cap
- SLNH 15.5M
- GOVX 16.8M
- IPO Year
- SLNH N/A
- GOVX N/A
- Fundamental
- Price
- SLNH $2.91
- GOVX $0.60
- Analyst Decision
- SLNH Hold
- GOVX Strong Buy
- Analyst Count
- SLNH 1
- GOVX 3
- Target Price
- SLNH N/A
- GOVX $10.67
- AVG Volume (30 Days)
- SLNH 16.7M
- GOVX 1.0M
- Earning Date
- SLNH 11-13-2025
- GOVX 11-07-2025
- Dividend Yield
- SLNH N/A
- GOVX N/A
- EPS Growth
- SLNH N/A
- GOVX N/A
- EPS
- SLNH N/A
- GOVX N/A
- Revenue
- SLNH $27,891,000.00
- GOVX $6,143,044.00
- Revenue This Year
- SLNH N/A
- GOVX N/A
- Revenue Next Year
- SLNH $42.68
- GOVX N/A
- P/E Ratio
- SLNH N/A
- GOVX N/A
- Revenue Growth
- SLNH N/A
- GOVX 1943.07
- 52 Week Low
- SLNH $0.36
- GOVX $0.43
- 52 Week High
- SLNH $5.14
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- SLNH 51.88
- GOVX 50.79
- Support Level
- SLNH $2.93
- GOVX $0.52
- Resistance Level
- SLNH $3.84
- GOVX $0.61
- Average True Range (ATR)
- SLNH 0.77
- GOVX 0.04
- MACD
- SLNH -0.12
- GOVX 0.01
- Stochastic Oscillator
- SLNH 27.57
- GOVX 72.18
About SLNH Soluna Holdings Inc.
Soluna Holdings Inc is a U.S.-based company that conducts operations through its subsidiary. The group is engaged in the mining of cryptocurrency through data centers that can be powered by renewable energy sources. The data centers buy every excess megawatt to use for batch-oriented, computing-intensive processes such as cryptocurrency mining or machine learning which is a low-risk and low-friction solution to use as a smartphone.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.